Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRandomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced NSCLC
Journal of Clinical Oncology, 10/20/09
Lee SM et al. – In this large trial of patients with NSCLC, thalidomide in combination with chemotherapy did not improve survival overall, but increased the risk of thrombotic events. Unexpectedly, survival was significantly worse in patients with nonsquamous histology.
Methods- 722patients were randomly assigned to receive placebo or thalidomide capsules 100 to 200 mg daily for up to 2 y
- All received gemcitabine and carboplatin every 3 weeks for up to 4 cycles
- End points overall survival (OS), progression-free survival (PFS), response rate, grade 3/4 toxicity, and quality of life (QoL)
- Median OS rates were 8.9 months (placebo) and 8.5 months (thalidomide)
- HR was 1.13 (95% CI, 0.97 to 1.32)
- 2-y survival rate 16% and 12% in placebo and thalidomide arms, respectively
- PFS results consistent with those for OS
- Risk of having thrombotic event increased by 74% in thalidomide group: HR of 1.74
- No differences in hematologic toxicities, but slight excess of rash and neuropathy in thalidomide group
- QoL scores similar but thalidomide associated with less insomnia, and more constipation and peripheral neuropathy
- In retrospective analysis, patients with nonsquamous histology in the thalidomide group had poorer survival: 2-y risk difference of 10%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer, 11/03/09
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
The Lancet Oncology, 11/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Sponsor
Article Search
Sponsor
Sponsor